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Abstract  
As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence 
(NICE) invited the manufacturer of vedolizumab (Takeda UK) to submit evidence of the clinical effectiveness 
and cost-effectiveness of vedolizumab for the treatment of patients with moderate-to-severe active &URKQ¶V
disease. The School of Health and Related Research (ScHARR) at the University of Sheffield was 
commissioned as the Evidence Review Group (ERG) and produced a critical review of the evidence for the 
clinical effectiveness and cost-HIIHFWLYHQHVVRIWKHWHFKQRORJ\EDVHGXSRQWKHFRPSDQ\¶VVXEPLVVLRQWR1,&(
The GEMINI II and GEMINI III trials formed the main supporting evidence for the intervention. Both studies 
were Phase III, multicentre, randomised, double-blind, placebo-controlled trials designed to evaluate the 
efficacy and safety of vedolizumab. They included patients who were naïve to tumour necrosis factor-alpha 
antagonist (anti-TNF-Į), and patients who had an inadequate response to, loss of response to, or intolerance to 
immunomodulators or anti-TNF-Į 7KH *(0,1, ,, WULDO ZDV GHVLJQHG WR HYDOXDWH WKH HIILFDF\ DQG VDIHW\ RI
vedolizumab as an induction treatment (dosing at weeks 0 and 2 with assessment at week 6) and maintenance 
treatment (weeks 6 to 52). In contrast, the GEMINI III trial was designed to evaluate the efficacy and safety of 
vedolizumab as an induction treatment only with doses at weeks 0, 2 and 6 with assessment at weeks 6 and 10.  
In the absence of any direct head-to-head randomised controlled trials comparing vedolizumab with other 
relevant biologic therapies (adalimumab and infliximab) for the treatment of moderate to severe &URKQ¶V
disease, the company conducted a network meta-analysis (NMA) which compared vedolizumab, adalimumab, 
infliximab and placebo for the outcomes of: clinical response, enhanced clinical response, clinical remission, 
and discontinuation due to adverse events. 
The company model estimated the incremental cost-effectiveness ratio (ICER) for vedolizumab compared with 
standard of care (consisting of 5-aminosalicylic acid [5-ASAs], corticosteroids and immunosuppressants) to be 
£21,620 per QALY gained within the anti-TNF-Į IDLOXUH SRSXODWLRQ (which included a confidential Patient 
Access Scheme for vedolizumab). The ICERs were above £30,000 per QALY gained for the mixed intention to 
treat (ITT) population (including both anti-TNF-Į naïve and failure population) and in patients who were anti-
TNF-ĮQDwYH only. The ERG identified a number of limitations which were believed to limit the robustness of 
the results presented by the company. These limitations could not be addressed by the ERG without major 
restructuring of the economic model. Therefore, the ERG concluGHG WKDW UHVXOWV IURP WKH FRPSDQ\¶V PRGHO
needed to be interpreted with caution and that it was unclear whether the ICERs would increase or decrease 
following amendment of the identified structural issues. 
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Key Points for Decision Makers 
x Vedolizumab appears to be more effective in both the induction and maintenance phase compared with 
placebo in patients with moderate-to-severe active CURKQ¶V GLVHDVH who have had an inadequate 
response to, loss of response to, or intolerance to conventional therapy or TNF-ĮLQKLELWRU+RZHYHUit 
is noted that the primary endpoint (clinical remission at week 6) in GEMINI III was not met, but was 
met at week ten.  
x The effectiveness of vedolizumab compared with adalimumab and infliximab is unknown and 
uncertain in the absence of a head-to-head randomised controlled trial and differences between studies 
included the network meta-analysis. 
x The ERG identified a number of OLPLWDWLRQVZLWK WKHFRPSDQ\¶VPRGHO which were believed to limit 
the robustness of the results presented by the company.  
x The National Institute for Health and Care Excellence Appraisal Committee recommended 
vedolizumab as an option for treating moderately to severely active &URKQ¶VGLVHDVHonly in patients for 
whom TNF-ĮDQWDJRQLVWVhas failed (that is the disease has responded inadequately or has lost response 
to treatment) or cannot be tolerated or is contra-indicated on the condition that the company provides 
vedolizumab with the discount agreed in the patient access scheme. 
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1. Introduction 
In order to be recommended for use within the National Health Service (NHS) in England, health technologies 
must be shown to be clinically effective and to represent a cost-effective use of NHS resources. The National 
Institute for Health and Care Excellence (NICE) is an independent organisation which provides national 
guidance and advice to improve health and social care. The NICE single technology appraisal (STA) process 
covers a single technology in a single indication, and is usually conducted soon after a UK marketing 
authorisation is granted [1]. The manufacturer of the technology submits a written submission to NICE, which 
GHWDLOVWKHFRPSDQ\¶VHVWLPDWHVRIWKHFOLQLFDOHIIHFWLYHQHVVDQGFRVW-effectiveness of the technology, together 
with an executable health economic model which provides estimates of cost per QALY. An independent 
external organisation (the Evidence Review Group [ERG]) reviews the submission in consultation with clinical 
specialists and produces an ERG report. The NICE Appraisal Committee then meets to make a decision based 
RQ WKHFRPSDQ\¶V Vubmission, the ERG report and testimony from experts and other stakeholders. Where the 
Committee decide to recommend a technology without restrictions a Final Appraisal Determination (FAD) is 
issued. Where the initial decision is to restrict or not recommend a technology, an Appraisal Consultation 
Document (ACD) is produced. Stakeholders are then invited to comment on the ACD and on the submitted 
evidence, after which a subsequent ACD may be produced or a FAD issued, which is open to appeal.  
 
This paper presents a summary of the ERG report [2, 3] for the STA of vedolizumab for the treatment of adults 
with moderate-to-severe active CURKQ¶VGLVHDVH&'DQGWKHVXEVHTXHQWGHYHORSPHQWRIWKH1,&(JXLGDQFHIRU
the use of this drug in England. Full details of all relevant appraisal documents, can be found on the NICE 
website.[4] 
 
2. The Decision Problem 
The prevalence of CD is approximately 50-100 per 100,000 patients with CD estimated to affect approximately 
60,000 patients in the UK in total [5]. CD is characterised by a chronic relapsing inflammation that mainly 
affects the gastrointestinal tract and is often accompanied by: abdominal pain, diarrhoea, weight loss, malaise, 
and anorexia [6, 7]. CD may also be complicated by stricturing (leading to intestinal obstruction), fistulae (often 
perianal), or abscesses [7].  
The diagnosis of CD combines patient history, physical symptoms, and evidence from imaging and laboratory 
studies [6]. Disease activity, in combination with phenotypic and endoscopic features, allows stratification of 
patients and selection of appropriate therapeutic strategies [6]. In clinical trials, the CD Activity Index (CDAI) 
has been widely used to describe disease activity [8] ± though the index is based on symptoms and does not 
capture intestinal mucosal activity or healing.  A simplified form, the Harvey Bradshaw Index may be used in 
trials and clinical practice.  
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The aim of drug treatment in CD is to induce and maintain remission and mucosal healing, with the optimal 
outcome of maintaining corticosteroid-free-remission and reducing complications and the need for 
hospitalisations and surgery [5].  
Existing guidelines [5, 7] VXJJHVW D VWDQGDUG µstep-XS DSSURDFK¶ for the treatment of CD in the UK. This 
involves the initial use of monotherapy with a conventional or locally released glucocorticosteroid to induce 
remission, escalating to the addition of azathioprine, mercaptopurine or methotrexate in those who do not 
respond.   
Infliximab and adalimumab are currently recommended as treatment options for adults with severe active CD 
whose disease has not responded to conventional therapy, or who are intolerant of or have contraindications to 
conventional therapy [9].  
Vedolizumab (brand name Entyvio®, Takeda UK) is a humanized monoclonal antibody that binds exclusively to 
WKH Įȕ LQWHJULQ RQ JXW-homing T helper lymphocytes and selectively inhibits adhesion of these cells to 
mucosal addressing cell adhesion molecule-1 (MAdCAM-1) and fibronectin, but not vascular cell adhesion 
molecule-1 (VCAM-1) [5]. Vedolizumab has a therapeutic indication for the treatment of adult with moderately 
to severely active CD who have had an inadequate response with, lost response to, or were intolerant to 
conventional therapy including anti-TNF-Į [10]. The recommended dosage of vedolizumab is 300 mg given by 
intravenous infusion at 0, 2 and 6 weeks and then every 8 weeks thereafter. In patients who have not shown a 
response by Week 10, an additional dose should be considered at that point resulting in a 0, 2, 6, 10 and 14 
schedule. The licensing states that treatment should be stopped if no evidence of therapeutic benefit is observed 
by Week 14 [10]. Finally, the licensing states that dose could be increased to every 4 weeks in patients who 
have experienced a decrease in their response. 
NICE issued a final scope [11] to appraise the clinical effectiveness and cost-effectiveness of vedolizumab, 
within its licensed indication, for the treatment of moderate-to-severe active CD in adults in whom the disease 
has responded inadequately to, or is no longer responding to, either conventional therapy or an anti-TNF-Į, or 
who are intolerant to either.  
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3. The Independent ERG Review 
The company provided a submission to NICE on the clinical and cost-effectiveness of vedolizumab for the 
treatment of patients with moderate-to-severe active CD [5].  The company submission (CS) [5] included a 
systematic review and network meta-analysis (NMA) of the clinical effectiveness literature and a model-based 
health economic analysis. 
 
In line with the STA process, the ERG critically reviewed the evidence presented in the company¶VVXEPLVVLRQ 
by assessing (i) whether the submission conformed to NICE methodological guidelines; (ii) whether the 
FRPSDQ\¶VLnterpretation and analysis of the evidence were appropriate; and (iii) the presence of other evidence 
or alternative interpretations of the evidence.  In addition, the ERG identified areas requiring clarification, for 
which the company provided additional evidence. 
 
3.1. Clinical Effectiveness Evidence Submitted by the Company 
The company [5] presented a systematic review of the clinical effectiveness and safety of vedolizumab for the 
treatment of moderately to severely active CD in adults in whom the disease has responded inadequately to, or is 
no longer responding to, either conventional therapy or an anti-TNF-Į, or who are intolerant to either of them. 
The systematic review aimed to assess the best available evidence to evaluate the efficacy and safety of all 
biological treatments (vedolizumab, adalimumab and infliximab) in patients with moderate to severe CD to 
inform a NMA.  
Two trials, GEMINI II [12] and GEMINI III [13] formed the main supporting evidence for the intervention. 
Both studies were Phase III, multicentre (GEMINI II 39 countries; GEMINI III 19 countries), randomised, 
double-blind, placebo-controlled trials designed to evaluate the efficacy and safety of vedolizumab and included 
patients who were naïve to an anti-TNF-ĮDQGpatients who had an inadequate response to, loss of response to, 
or intolerance to immunomodulators or an anti-TNF-Į 
The GEMINI II trial [12] was designed to evaluate the efficacy and safety of vedolizumab as an induction 
treatment (dosing at weeks 0 and 2 with assessment at week 6) and maintenance treatment (weeks 6 to 52, every 
4 or 8 weeks). In contrast, the GEMINI III trial [13] was designed to evaluate the efficacy and safety of 
vedolizumab as an induction treatment only, with a dosing regimen of weeks 0, 2 and 6 with assessment at 
weeks 6 and 10. In general, efficacy analyses in the GEMINI II and III trials [12, 13] were conducted according 
to the intention-to-treat (ITT) principle whereby patients who withdrew prematurely were considered as 
treatment failures.  
For the 6 week induction phase of the GEMINI II trial [12], 368 individuals were randomised (3:2 ratio) to 
receive 300mg vedolizumab i.v. or placebo (as saline) at Weeks 0 and 2 (Cohort 1). In order to fulfil sample size 
requirements for the maintenance study, an additional 748 individuals were enrolled in an open-label group 
(Cohort 2), which also received 300mg vedolizumab i.v. For the maintenance phase, patients from both cohorts 
(Cohort 1 and Cohort 2) who had a clinical response (defined as > 70 point decrease in the CDAI score) to 
vedolizumab at week 6 were randomised (1:1:1 ratio) to double-blind treatment with vedolizumab 300mg i.v. 
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every 8 weeks (with placebo administered every other visit to preserve blinding), vedolizumab 300mg i.v. every 
4 weeks or placebo every 4 weeks for up to 52 weeks. Randomisation was stratified by three factors: (1) cohort; 
(2) concomitant use/non-use of glucocorticoids; and (3) concomitant use/non-use of immunosuppressive agents 
or prior use/non-use of anti-TNF-Į RU ERWK The two primary endpoints in the induction trial phase were 
enhanced clinical response at week 6 (defined as >100-point decrease in CDAI score), and clinical remission at 
week 6 (defined as a CDAI score of <150 points). The primary endpoint for the maintenance trial phase was 
clinical remission at week 52. Secondary outcome measures included enhanced clinical response at 52 weeks, 
glucocorticoid-free remission at week 52 in patients receiving glucocorticoids at baseline, and durable clinical 
remission (defined as clinical remission at > 80% of study visits, including the final visit). The proportion of 
patients meeting these end points was analysed. 
During the 10 week induction phase of the GEMINI III trial [13], 416 individuals were enrolled.  315 
individuals had a previous inadequate response to, loss of response to, or intolerance of one or more anti-TNF-
Įs and 101 individuals were naïve to an anti-TNF-ĮPatients were randomly assigned to receive intravenous 
vedolizumab (300mg) or placebo (as saline) at week 0, week 2, and week 6, with three stratification factors: (1) 
the presence or absence of previous anti-TNF-ĮIDLOXUHFRQFRPLWDQWXVHQRQ-use of glucocorticoids; and (3) 
by concomitant use/non-use of immunosuppressive agents. The primary endpoint in the GEMINI III trial [13] 
focussed on patients for whom an anti-TNF-Į KDV IDLOHG LH DQ LQDGHTXDWH UHVSRQVH WR ORVV RI SULPDU\
response to, loss of secondary response to, or intolerance of >1 anti-TNF-ĮDQGZDVWKHSURSRUWLRQRIpatients 
LQFOLQLFDOUHPLVVLRQ&'$,VFRUHSRLQWVDWZHHN$secondary analysis evaluated an overall population 
which included patients who were naïve to anti-TNF-Į DQG SUH-specified exploratory analyses examined the 
group naïve to an anti-TNF-Į 
Key efficacy data for both trials are presented in Table 1. Only results for the primary outcomes are summarised 
here. Further efficacy data can be found in the company submission [5] and the ERG report [2, 3]. 
In GEMINI II [12], patients treated with vedolizumab had significantly higher rates of clinical remission (CDAI 
VFRUHSRints) at week 6 compared with placebo (14.5% versus (vs) 6.8%, treatment difference of 7.8% 
(95% CI 1.2, 14.3; p = 0.0206)) in the ITT population. In the anti-TNF-ĮIailure population of GEMINI III [13], 
there was no statistically significant difference in the proportion of patients achieving clinical remission at week 
6 between vedolizumab and placebo (15.2% vs 12.1%, treatment difference 3.0% (95% CI -4.5 to 10.5, 
p=0.433), and thus vedolizumab was not statistically significantly better than placebo with respect to the 
primary outcome. Therefore, statistical evaluations of all remaining endpoints in GEMINI III were considered 
exploratory. For the full recruited population of GEMINI III, the exploratory analysis reported a statistically 
significant difference in favour of vedolizumab (19.1% vs 12.1%, treatment difference 6.9% (95% CI 0.1 to 
13.8, p=0.0478) for clinical remission at week 6. Only GEMINI III reported results at 10 weeks, and both the 
anti-TNF-ĮIDLOXUHSRSXODWLRQDQGWKHZKROHUHFUXLWHGSRSXODWLRQUHSRUWHGVWDWLVWLFDOO\VLJQLILFDQWGLIIHUHQFHV in 
clinical remission in the exploratory analyses (14.4% (95% CI 5.7 to 23.1, p=0.0012) and 15.5% (95% CI 7.8 to 
23.3, p< 0.0001) respectively).  
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Table 1: Summary of key efficacy outcomes. 
Ph
as
e 
Treatment schedule N CR 
 
ECR 
 
n (%) (95% CI) Comparison 
Adjusted % difference 
(95% CI, P value)  
RR (95% CI) n (%) (95% CI) Comparison 
Adjusted % difference 
(95% CI, P value) 
RR, (95% CI) 
In
du
ct
io
n
 
ph
a
se
 
Gemini II, Mixed ITT, 6 weeks  
Vedolizumab, wk 0, wk 6  220 32 (14.5) ( 9.9 to 19.2)* 
 
7.8 (1.2 to 14.3, 
p=0.0206)* 
  
 
2.1 (1.1 to 4.2)* 69 (31.4) (25.2 to 37.5)* 5.7 (-3.6 to 15.0, 
p=0.2322)* 
 
 
1.2 (0.9 to 1.7)* 
Placebo  148 10 (6.8) (2.7 to 10.8)* 38 (25.7) (18.6 to 32.7)* 
Gemini III, Prior TNR- Į-failure, 6 weeks  
Vedolizumab, wk 0, 2 and 6 158 24 (15.2) (9.6 to 20.8)* 
 
3.0 (-4.5 to 10.5, 
p=0.433)* 
 
 
1.2 (0.7 to 2.2)* 62 (39.2) (31.6 to 46.9) 16.9 (6.7 to 27.1, n/a)** 
 
 
2.2 (1.3 to 3.6)** 
 
Placebo 157 19 (12.1) (7.0 to 17.2)* 35 (22.3) (15.8 to 28.8) 
Gemini III, Mixed ITT, 6 weeks  
Vedolizumab, wk 0, 2 and 6 209 40 (19.1) (13.8 to 24.5)** 6.9 (0.1 to 13.8, 
p=0.0478) ** 
 
 
1.6 (1.0 to 2.5) ** 82 (39.2) (32.6 to 45.9) ** 16.4 (7.7 to 25.2, p=n/a) 
** 
 
 
1.7 (1.3 to 2.3) ** 
Placebo 207 25 (12.1) (7.6 to 16.5) ** 47 (22.7) (17.0 to 28.4) ** 
Gemini III, Prior TNF-Į-failure, 10 weeks   
Vedolizumab, wk 0, 2 and 6 158 42 (26.6) (19.7 to 33.5) ** 14.4 (5.7 to 23.1, 
p=0.0012) ** 
 
 
2.2 (1.3 to 3.6) ** 74 (46.8) (39.1 to 54.6) ** 22 (11.4 to 32.6, p=n/a) 
** 
 
 
1.9 (1.4 to, 2.6) 
Placebo 157 9 (12.1) (7.0 to 17.2) ** 39 (24.8) (18.1 to 31.6) ** 
Gemini III, Mixed ITT, 10 weeks  
Vedolizumab, wk 0, 2 and 6 209 60 (28.7) (22.6 to 34.8) ** 15.5 (7.8 to 23.3, p< 
0.0001) ** 
  
 
2.2 (1.4 to 3.3) ** 100 (47.8) (41.1 to 54.6) ** 23.7 (14.5 to 32.9, 
p=n/a) ** 
 
 
2.0 (1.5 to 2.6) 
Placebo 207 27 (13.0) (8.5 to 17.6) ** 50 (24.2) (18.3, 30.0) ** 
M
a
in
te
n
a
n
ce
 
ph
a
se
 
Gemini II, Mixed ITT, 52 weeks  
Vedolizumab, Q8W 
 
154 60 (39.0) (31.3 to 46.7)* Vedolizumab, Q8W* 
17.4 (7.3 to 27.5, 
p=0.0007) 
 
Vedolizumab, Q4W* 
14.7 (4.6 to 24.7, 
p=0.0042) 
 
Vedolizumab, 
Q8W* 
1.8 (1.3, 2.6) 
 
Vedolizumab, 
Q4W* 
1.7 (1.2 to 2.4) 
67 (43.5) (35.7, 51.3) Vedolizumab, Q8W 
13.4, (2.8 to 24.0), 
p=0.0132) 
 
Vedolizumab, Q4W 
15.3, (4.6 to 26.0, 
p=0.0053) 
 
Vedolizumab, Q4W* 
1.4 (1.1, 1.9) 
 
Vedolizumab, Q4W 
1.5 (1.1 to 2.0) 
Vedolizumab, Q4W 
 
154 56 (36.4) (28.8 to 44.0)* 70 (45.5) (37.6, 53.3) 
Placebo 153 33 (21.6) (15.1 to 28.1)* 46 (30.1) (22.8, 37.3) 
Z ?ůŝŶŝĐĂůƌĞŵŝƐƐŝŽŶĚĞĨŝŶĞĚĂƐ/ƐĐŽƌĞA䜀  ? ? ?ƉŽŝŶƚƐ ?Z ?ŶŚĂŶĐĞĚĐůŝŶŝĐĂůƌĞƐƉŽŶƐĞĚĞĨŝŶĞĚĂƐĂA? ? ? ?-ƉŽŝŶƚƌĞĚƵĐƚŝŽŶŝŶ/ƐĐŽƌĞĨƌŽŵďĂƐĞůŝŶĞ ?^Z ?^ƵƐƚĂŝŶĞĚĐůŝŶŝĐĂůƌĞŵŝƐƐŝŽŶĚĞĨŝŶĞĚĂƐ/ƐĐŽƌĞA䜀  ? ? ?ƉŽŝŶƚƐĂƚďŽƚŚǁĞek 6 and 
week 10; Vedo, vedolizumab; CI, confidence interval; RR, relative risk; Q8W, vedolizumab treatment every 8 weeks; Q4W, vedolizumab treatment every 4 weeks; NR, not reported; N/A, not available; TNF, tumour necrosis factor 
* Primary outcomes 
** These outcomes were classified as exploratory analyses as the primary outcome (CR at 6 weeks for the prior TNF-ɲ-failure population) was not met. 
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There was no significant difference between the vedolizumab and placebo groups for the second primary 
outcome in GEMINI II [12] which analysed the number of patients achieving enhanced clinical response 
(defined as a 100-point reduction from baseline in CDAI score) at week 6. 
In the maintenance phase of the GEMINI II trial [12], 48% (242/461) of patients discontinued from the study. 
Patients treated with vedolizumab every 8 weeks and every 4 weeks, had significantly higher rates of clinical 
remission at week 52 compared with placebo (treatment difference 17.4% (95% CI 7.3 to 27.5, p = 0.0007) and 
14.7% (95% CI 4.6, 24.7; p = 0.0042) respectively).  
In the absence of any direct head-to-head randomised controlled trials comparing vedolizumab to other relevant 
biologic therapies (adalimumab and infliximab) for the treatment of moderate to severe CD, the company 
conducted an NMA [5]. The NMA, as reported in the CS [5], compared vedolizumab, adalimumab, infliximab 
and placebo for the outcomes of: clinical response, enhanced clinical response, clinical remission, and 
discontinuation due to adverse events (AEs). Data were from the trials GEMINI II [12], GEMINI III [13], 
CLASSIC I [14], Targan et al(1997) [15], NCT00105300 [16], NCT00445939 [17] EXTEND [18], ACCENT I 
[19], CLASSIC II [20], NCT00445432 [17], and CHARM [21].  The size of the network for each outcome 
varied depending on the availability of the data in each study.  
In the induction phase for the anti-TNF-Į QDwYH population IRU FOLQLFDO UHVSRQVH GURS LQ &'$,  DOO
treatments were statistically significantly effective versus placebo. Infliximab was statistically significantly 
better than vedolizumab. For clinical remission, all treatments except adalimumab 40/20mg (dose not licensed 
in the UK) were statistically better than placebo. In pairwise comparisons, infliximab was statistically 
significantly better than vedolizumab at 10 and 6 weeks; vedolizumab had a better odds ratio (OR) versus 
placebo than adalimumab 80/40mg dose, but worse OR versus placebo than adalimumab 160/80mg, but neither 
comparison was statistically significant.  For discontinuations due to AEs, adalimumab 160/80mg dose was 
significantly better (lower) than vedolizumab; there were no data available for infliximab.  
In the maintenance phase for the anti-TNF-Į naïve population, vedolizumab every 4 weeks was only statistically 
different to placebo for the outcome of clinical remission. Vedolizumab every 8 weeks was statistically 
significantly better than placebo for both clinical response and clinical remission. Infliximab was statistically 
different from placebo in all three outcomes (clinical remission, clinical response, discontinuation due to AEs).  
The statistical significance of the difference in clinical response between vedolizumab and infliximab was not 
reported for the standard dose (5mg) of infliximab licenced in the UK, but infliximab 10mg was statistically 
significantly better than vedolizumab every 4 weeks. The clinical response OR for infliximab 5mg versus 
placebo was better than that for both vedolizumab every 4 weeks and every 8 weeks (dose every 4 weeks is 
licensed in the UK for patients who have experienced a decrease in their response only. It was not clear if 
patients in this analysis met this criteria).  The difference between vedolizumab and infliximab for the outcome 
FOLQLFDO UHPLVVLRQ ZDV QRW VWDWLVWLFDOO\ VLJQLILFDQW 7KHUH ZDV D KLJK 25 IRU GLVFRQWLQXDWLRQ GXH WR $(¶V
compared to placebo for infliximab; vedolizumab was significantly better than infliximab for discontinuations 
due to AEs. 
No statistically significant differences were observed for most outcomes between vedolizumab and adalimumab 
in the induction phase for anti-TNF-ĮH[SHULHQFHGIDLOXUHQetwork. A network for anti-TNF- ĮIDLOXUHVXEJURXSV
was not possible for maintenance due to lack of data. 
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3.1.1. Critique of Clinical Effectiveness Evidence and Interpretation 
The ERG considered the systematic review process followed by the company to be satisfactory, although the 
details were not reported fully in the CS [2] but provided in a separate document (commercial in confidence). 
'HVSLWHPLQRUOLPLWDWLRQVLQWKHFRPSDQ\¶VVHDUFKVWUDWHJ\WKH(5*was confident that all relevant studies of 
vedolizumab were included in the CS [2]. The specified inclusion and exclusion criteria appeared generally 
appropriate, though lacking in detail in places, and reflected the information given in the decision problem. The 
YDOLGLW\ DVVHVVPHQW WRRO XVHG WR DSSUDLVH WKH LQFOXGHG VWXGLHV DV VXJJHVWHG E\ 1,&(¶V 6SHFLILFDWLRQ )RU
Company/Sponsor Submission Of Evidence template [22], was based on the quality assessment criteria for 
RCTs and was considered appropriate by the ERG [2]. 
The efficacy and safety of vedolizumab was positively demonstrated in GEMINI II [12]. Owing to the high 
discontinuation rates in the maintenance phase of the GEMINI II trial, estimates of treatment effects (including 
magnitude) may be affected. The imputation of missing patients as failures should, however, limit the impact of 
attrition on estimates of efficacy to underestimation of treatment effects, though the effect of attrition may be 
more problematic for safety outcomes and lead to underestimates of AEs. The trials assess response in the 
induction phase earlier than would be done in the UK, at six weeks compared to ten weeks. As such, the 
population entering the maintenance phase in GEMINI II [12] may not fully be representative of the UK 
spectrum, as patients who take longer to respond are excluded. This could conceivably lead to an overestimation 
of maintenance treatment effect, if these patients are also less likely to maintain a response when in remission. 
In addition, the trial of maintenance therapy was not of sufficient size or duration to estimate the risk of 
uncommon AEs. The primary endpoint was not achieved in GEMINI III [13]; therefore, statistical evaluation of 
the secondary endpoints was acknowledged as exploratory by the company. 
The ERG considered that the results preVHQWHGLQWKHFRPSDQ\¶V10$PD\KDYHXQGHUHVWLPDWHGWKHXQFHUWDLQW\
in treatment effects since fixed effects models were used [5]. The networks included in the CS [5] were of 
varying quality and relevance. The results of the ³HQWLUHSRSXODWLRQ´QHWZRUNVZHUH WKRXJKW WREHGLIILFXOW WR
interpret, as study populations were too heterogeneous in terms of potentially important treatment modifying 
effects [2]. The anti-TNF-ĮIDLOXUHQHWZRUNPD\KDYHRYHUHVWLPDWHGHIILFDF\IRUDGDOLPXPDEDVSULPDU\DQWL-
TNF-Į IDLOXUH patients were excluded from the adalimumab study but not the vedolizumab studies. Several 
studies across the evidence base excluded patients with strictures, meaning generalisation to this population is 
problematic, and most did not report the proportion of patients with fistulising disease, so it is unclear whether 
all studies were representative of UK populations in this respect [2]. Similarly no studies included patients with 
CDAI>450, meaning generalisation to severe patients (if defined as CDAI 450 to 600) is problematic. 
8QFHUWDLQW\UHPDLQVDURXQGKRZWKHFRPSDUDWRU³XVXDOFDUH´SURYLGHGLQ studies compares with UK practice. 
No analysis for serious AEs was provided for the anti-TNF-ĮQDwYHQHWZRUNV$GGLWionally, for the induction 
networks, there were limitations with the induction schedule used in the trials included, with fewer doses than 
recommended being provided, and/or assessments taking place earlier than would be done in UK practice or 
than stated in the licence. Maintenance networks were subject to potential bias from the recruitment of patients 
on the basis of assessment at earlier time points that would commonly be done in the UK. 
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3.2. Cost-Effectiveness Evidence Submitted by the Company  
The company submitted a model-based health economic analysis as part of their submission to NICE, which 
was subsequently revised. The analysis was undertaken from the perspective of the NHS over a 10-year time 
horizon. All costs and health outcomes were discounted at a rate of 3.5% per annum in accordance with NICE 
guidance. 7KHFRPSDQ\¶VDQDO\VLVwas presented for three populations: (1) the mixed-ITT population, which is 
comprised of patients who have previously received anti-TNF-ĮWKHUDS\DQGWKRVHZKRDUHDQWL-TNF-ĮQDwYH
(2) patients who are anti-TNF-ĮQDwYHRQO\DQG patients who have had anti-TNF-Įonly. Within all three 
analyses, comparators included conventional non-biologic therapies (a combination of 5-ASAs, 
immunomodulators and corticosteroids). Other anti-TNF-ĮDJHQWVLQIOL[LPDEDGDOLPXPDEwere included only 
in the analysis of the anti-TNF-ĮQDwYHVXEJURXSWKHVHDUHH[FOXGHGIURPWKHDQDO\VHV of the mixed-ITT and 
anti-TNF-ĮIDLOXUHVXEJURXSV 
7KHFRPSDQ\¶VPRGHO  structure was based on the structure published by Bodger et al [23] and adopted a hybrid 
approach whereby a decision tree is used to evaluate outcomes at the end of the initial induction therapy during 
which all patients receive initial treatment to induce response. The induction period is assumed to be 6 weeks for 
all biologic and non-biologic therapy. A Markov structure (8-week cycle) is used afterward to evaluate 
subsequent outcomes. The model is composed of a total of 12 mutually exclusive and exhaustive health states, 
according to the treatment received, severity of the condition and surgery.  
 
Figure 1 Decision-tree for induction WUHDWPHQWUHSURGXFHGIURPFRPSDQ\¶VVXEPLVVLRQ 
 
 
a
 Response is defined as a drop in CDAI of 70 points or more; * The Markov structures; AE = DGYHUVHHYHQW&'$, &URKQ¶V'LVHDVH
Activity Index; CT = conventional therapy. 
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Figure 2  Markov model schematics for CD maintenance phase and beyond (reproduced 
IURPFRPSDQ\¶VVXEPLVVLRQ) 
 
a
 Reasons for discontinuation include lack of response and adverse events. Discontinuation due to adverse events is applicable only to 
responders on biologic treatments, because non-responders on biologics switch to conventional therapy and continue receiving such until the 
HQGRIWKHPRGHO¶VWLPHKRUL]RQ 
b
 Patients may transition to death from any health state during any cycle. 
 
.H\HIILFDF\SDUDPHWHUV XVHG ZLWKLQ WKH FRPSDQ\¶V PRGHO were either (i) observed or (ii) derived and taken 
from the two pivotal trials (GEMINI II & III [12, 13]) for vedolizumab and from the NMA for the anti-TNF-Į
[5]. Key parameters are the transition probabilities in the maintenance phase. These were µFDOLEUDWHG¶XVLQJWKH
Solver function within Excel so that (a) the proportion of patients in remission at the end of the maintenance 
treatment (approximately at one-\HDUSUHGLFWHGE\WKHPRGHOPDWFKHVWKHµH[SHFWHG¶SURSRUWLRQRIpatients in 
remission at the end of the maintenance phase and (b) the proportion of patients with mild disease at the end of 
WKHPDLQWHQDQFHSKDVHSUHGLFWHGE\WKHPRGHOPDWFKHVWKHµH[SHFWHG¶SHUFHQWDJHRIUHVSRQGHUVWRWKHLQGXFWLRQ
phase with a drop of 70 points of more in the CDAI score and not in  remission at the end of the maintenance 
phase. AEs were included in the model and the EQ-5D utility scores from the GEMINI trials [12, 13] were used 
to represent the utility values for the disease health states. Management costs (healthcare resource use associated 
with inpatient, outpatients visits, investigations and medications) for the different health states were taken from 
Bodger et al [23] and uplifted to 2012. 
Key results provided by the company are presented here. The full list of results are available in the CS [5]. 
Within the anti-TNF-ĮQDwYHVXEJURXSWKHFRPSDQ\UHSRUWed the ICER for vedolizumab versus adalimumab to 
be £758,344 per QALY gained and infliximab versus vedolizumab to be £26,580 per QALY gained [5]. Based 
on a fully incremental analysis (performed by the ERG), vedolizumab was subject to extended dominance [2]. 
Within the anti-TNF-ĮIDLOXUHVXEJURXSWKHFRPSDQ\UHSRUWHGWKH,&(5IRUYHGROL]XPDEYHUVXVFRQYHQWLRQDO
non-biologic therapy to be £98,452 per QALY gained in its original submission to NICE [5]. Following the 
publication of the appraisal consultation document (ACD) [24], the company submitted a revised economic 
model which included the following modifications: 
x focusing on patients for whom a TNF-ĮDQWDJRQLVWKDVIDLOHGLHDQLQDGHTXDWHUHVSRQVHWR ORVVRI
response to, or intolerance of >1 TNF-ĮDQWDJRQLVW 
x employing a lifetime horizon, 
x using an assessment time of response in line with its licensing [10],  
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x inclusion of a revised patient access scheme, 
x amendment of inputs and assumptions including assumptions around mortality and updating the health 
state costs using resource use estimated through a survey conducted amongst 8 clinical experts rather 
than the costs reported from Bodger et al (2009) [23],  
x amendments to the Markov trace and calculations. 
 
7KHVHKDGWKHHIIHFWRIUHGXFLQJWKHFRPSDQ\¶VEDVHFDVHGHWHUPLQLVWLFSUREDELOLVWLF,&(5IURPQRW
reported) per QALY gained [5] to £21,620 (£27,428) per QALY gained [25] within the anti-TNF-Į IDLOXUH
population. 
 
3.2.1. Critique of Cost-Effectiveness Evidence and Interpretation 
The ERG [2, 3] FULWLFDOO\DSSUDLVHGWKHFRPSDQ\¶VKHDOWKHFRQRPLFDQDO\Ves and the models upon which these 
analyses were based. In summary, the ERG identified a number of limitations with the main limitations 
described below. The ERG noted that the combination of all these issues leads to discrepancies between the 
model prediction and trial data in terms of the proportion of patients in remission in the placebo arm and 
responders to vedolizumab to the induction phase remaining on treatment and discontinuing treatment.  
3.2.1.1. Limitations regarding the model structure/key structural assumptions 
Whilst the model structure is based on a previous economic evaluation by Bodger et al [23], the ERG [2] noted 
the following: (a) tKHFRPSDQ\¶VPRGHOFDSWXUHVWZRNH\DVSHFWVRIWKHFRQGLWLRQFKDQJHVLQGLVHDVHVHYHULW\
(measured by the CDAI score) and the risk of surgery. The model ignores a key aspect of the condition in that 
CD is relapsing (exacerbation) and remitting (some patients may improve spontaneously), (b) surgery is 
modelled as a single health state representing a mix of procedures (c) the difficulty associated with 
SDUDPHWHULVLQJ WKH FRPSDQ\¶V FKRVHQ VWUXFWXUH which led the company to make a series of assumptions and 
adjustments that are not adequately justified by the evidence, and (d) debatable key structural assumptions. 
These debatable structural assumptions include the assumption that non-responders have moderate to severe 
disease; the lack of distinction between responders and non-responders with moderate to severe CD; the 
assumption of the same induction phase duration for all therapy; the relevance to clinical practice of drop of 70 
or more in CDAI score to identify patients going onto receive maintenance treatment; end of scheduled 
maintenance at approximately 1-year; potentially optimistic assumption following discontinuation whilst on 
biologics and omission of discontinuation due to lack of efficacy. 
 
3.2.1.2. Generalisability of the population 
The ERG [2] further noted that the population included in the economic model was based on the GEMINI trials 
[12, 13] which only included patients with a CDAI score between 220 and 450 and therefore may not be 
representative of clinical practice in England. The trial recruited from a large number of centres worldwide and 
therefore, conventional non-biologic therapy may not be generalizable to England. The ERG noted that 
interpretation of results and the relevance of the mixed-ITT population to the decision problem was open to 
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debate. The ERG believed that patients who have previously received anti-TNF-ĮDJHQWVDQGWKRVHZKRDUHDQWL-
TNF-ĮQDwYHDUHWZRGLVWLQFWGHILQHGSDWLHQWJURXSVZLWKGLIIHUHQWFKDUDFWHULVWLFVDQGSURSHQVLWLHVWRUHVSRQG
to treatment, as demonstrated in the GEMINI trials [12, 13]. The appropriate comparators as chosen by the 
company are also different within these two populations. As such the ERG believes that the use of vedolizumab 
in these groups represents two separate decisions. 
 
3.2.1.3. Comparators and treatment regimens 
7KHFRPSDQ\¶VDQDO\VLVZLWKLQWKHDQWL-TNF-ĮIDLOXUHVXEJURXSH[FOXGHVDOORWKHUELRORJLFWKHUDS\+RZHYHU
the use of a second anti-TNF-Į DJHQW IROORZLQJ WKH IDLOXUH RI D ILUVW DQWL-TNF-Į DJHQW PD\ EH SRVVLEOH
particularly where loss of response has occurred due to development of antibodies to the first anti-TNF-Į
therapy; however, the ERG recognises the limited efficacy evidence available. 
The ERG had concerns with the treatment regimens DVVXPHG LQ WKH FRPSDQ\¶V PRGHO Notably, despite 
biologics having different treatment regimens, the company assumed the same induction phase duration for all 
therapies (6 weeks in the original model and 10 weeks in the revised model), adjusting the cost accordingly 
OHDGLQJWRGLVFUHSDQFLHVLQWKHFRPSDQ\¶VPRGHOLQWHUPVRIFRVWLng, cycle length and efficacy). 
 
3.2.1.4. 3DUDPHWHULVDWLRQRIWKHFRPSDQ\¶VPRGHO 
The ERG [2] discussed the efficacy data that were used in the economic model, notably the comparability of 
data for the different biologics at the maintenance phase, the efficacy data used for conventional non-biologic 
treatment, the partial use of the NMA and lack of clarity of the derivation of inputs - in particular, the derivation 
of the transition probabilities during the maintenance phase which were µFDOLEUDWHG¶ The ERG observed that the 
calibration approach was complex and may have been unnecessary as patient-level data from the GEMINI II 
trial [12] were available and could have been used to estimate the transition probabilities in the maintenance 
phase in patients treated with conventional non-biologic therapy and vedolizumab. The ERG identified a 
number of limitations with the calibration approach used by the company, notably that the target data-points 
used in the fitting process seemed inconsistent with the data point the model was fitted to and that the derivation 
of the transition probabilities was dependent on structural assumptions and input parameters. Transition 
probabilities were assumed to be constant and applied for the remainder of the model which was uncertain given 
the lack of evidence after one year.  
Whilst the ERG [2, 3] recognised that there may be limitations with health state costs taken from Bodger et al 
(2009) [23], using costs estimated from the clinician survey conducted by the company may also have been 
inaccurate. This is particularly important given that this amendment to health state costs had a considerable 
impact on the ICER. The revised base-case ICER estimated by the company was £21,620 per QALY gained 
using the updated cost for the CD health states based on the clinician survey. Using the original management 
cost for the CD health states from Bodger et al (2009) [23] increased the ICER to £46,025 per QALY gained. 
 
3.3. Additional work undertaken by the ERG 
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The key issues described above could not be addressed by the ERG [2, 3] without major restructuring of the 
economic model which was not achievable with the time frame for this STA. Incorporating changes to the 
model was challenging given the structure of the model and lack of transparency. As a result, the ERG was not 
able to amend the economic model structure. 
However, the ERG [2, 3] conducted additional scenarios analyses where possible which included removing 
AEs, change utility values associated with the surgery health state, amendments to the cost of adalimumab, 
assuming the same efficacy in the maintenance phase between the different biologics, accounting for lack of 
efficacy and assuming the same excess mortality rate for each CD health state. In summary, the additional 
exploratory analyses conducted by the ERG had a limited impact on the ICER in isolation (variation in the 
ICER less than 5%). 
 
 
3.4. Conclusion of the ERG Report 
Compared with placebo, the addition of vedolizumab to standard care in patients with moderately to severely 
active CD who had an inadequate response to, loss of response to, or intolerance of conventional therapy or anti-
TNF-Į ZDV VLJQLILFDQWO\ PRUH HIIHFWLYH LQ WHUPV RI UHPLVVLRQ GHILQHG DV &'$, <150) at week 6 in the 
induction phase of GEMINI II [12]. However, in GEMINI III [13] there was no statistically significant 
difference between vedolizumab and placebo in the primary endpoint of the proportion of patients achieving 
FOLQLFDOUHPLVVLRQDWZHHN&'$,VFRUHSRLQWVLQWKHDQWL-TNF-ĮIDLOXUHSRSXODWLRQ 
In the maintenance phase of GEMINI II [12] patients treated with vedolizumab every 8 weeks and every 4 
weeks, had significantly higher rates of clinical remission at week 52 (defined as CDAI score of < 150 points) 
compared with placebo.  
There are, however, a number of limitations and uncertainties in the evidence base which warrant caution in its 
interpretation. Key issues relate to the high attrition rates in the maintenance phase of the GEMINI II [12] trial, 
the uncertainty on the long-term treatment effect, the duration of optimal therapy and how and when withdrawal 
should be introduced. The primary endpoint was also not achieved in GEMINI III; therefore, statistical 
evaluation of the secondary endpoints is exploratory. Results presented in the NMA are highly uncertain. 
Changes made by the company in the revised economic model following the ACD had the effect of reducing the 
FRPSDQ\¶V EDVH FDVH GHWHUPLQLVWLF SUREDELOLVWLF ,&(5 IURP  QRW UHSRUWHG in the CS) to £21,620 
(£27,428) per QALY gained for the anti-TNF-Į IDLOXUH SRSXODWLRQ [25]. It should be noted that most of the 
changes were attributable to two amendments that are subject to uncertainty: increasing the time horizon from 
10 years to a lifetime; and updating the health state costs using resource use estimated through a survey 
conducted amongst clinical experts.  
The ERG [2, 3] identified a number of limitations which were believed to limit the robustness of the results 
presented by the company. These limitations could not be addressed by the ERG without major restructuring of 
the economic model. 7KHUHIRUH WKH (5* FRQFOXGHG WKDW UHVXOWV IURP WKH FRPSDQ\¶V PRGHO QHHGHG WR EH
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interpreted with caution and that it was unclear whether the ICERs would increase or decrease following 
amendment of the identified structural issues. 
 
4. Key Methodological Issues 
The NMAs included in the CS [5] were also of varying quality and relevance. There was heterogeneity in the 
population and outcomes included in the studies that participated to the network. 7KHFRPSDQ\¶V10$is also 
likely to have underestimated the uncertainty in treatment effects since fixed effects models were used.   
The health economic model submitted by the company was subject to a number of methodological issues which 
limited the credibility of the company¶V UHVXOWV [2] including: the potential omission of key aspects of the 
condition such as the relapsing-remitting nature of CD; simplifying and debatable assumptions regarding 
surgery; WKHGLIILFXOWO\DVVRFLDWHGZLWKSDUDPHWHULVLQJWKHFRPSDQ\¶VFKRVHQmodel structure; most notably the 
derivation of the transition matrices; and debatable key structural assumptions. The combination of all these 
issues led to some discrepancies between the model prediction and observed trial data. These issues could not 
addressed by the ERG without major restructuring of the economic model. 
 
5. National Institute for Health and Care Excellence Guidance 
The Appraisal Committee reviewed the data available on the clinical and cost-effectiveness of vedolizumab, 
having considered evidence on the nature of moderate-to-severe active CD and the value placed on the benefits 
of vedolizumab by patients with the condition, those who represent them, and clinical experts. It also took into 
account the effective use of NHS resources.  
In December 2014, the Appraisal Committee produced a preliminary negative recommendation [24] for the use 
of vedolizumab within its marketing authorisation, i.e in adults whose disease has responded inadequately to, or 
has lost response to, either conventional therapy or a anti-TNF-Į, or who cannot tolerate either of these 
treatment types. 
As part of the appraisal consultation process, the company provided further analyses of the GEMINI II [12] and 
GEMINI III [13] trials on patients for whom a TNF-ĮDQWDJRQLVWKDVIDLOHGLHDQLQDGHTXDWHUHVSRQVHWRORVV
of response to, or intolerance of >1 TNF-ĮDQWDJRQLVW [25] and submitted a revised economic model focusing 
on the anti-TNF-ĮIDLOXUHSRSXODWLRQincluding a revised patient access scheme. 
Following consideration of the evidence presented on the clinical and cost-effectiveness of vedolizumab in 
patients for whom a TNF-ĮDQWDJRQLVWKDVIDLOHG [25], NICE issued its final guidance [4] in August 2015 and 
recommended the use of vedolizumab as an option for treating moderately to severely active CD only if: 
x an anti-TNF-Į has failed (that is the disease has responded inadequately or has lost response to 
treatment) or  
x an anti-TNF-Įcannot be tolerated or is contra-indicated.  
x only if the company provides vedolizumab with the discount agreed in the patient access scheme.  
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The guidance [4] also states that vedolizumab should be given as a planned course of treatment until it stops 
working or surgery is needed, or until 12 months after the start of treatment, whichever is shorter. The guidance 
recommends that at 12 months, patients should be reassessed to determine whether treatment should continue 
and that treatment should only continue if there is clear evidence of ongoing clinical benefit. The guidance [4] 
recommends that for patients in complete remission at 12 months, the cessation of vedolizumab should be 
considered, with treatment being resumed if there is a relapse. The guidance recommends that patients receiving 
vedolizumab should be reassessed at least every 12 months to decide whether continued treatment is justified.  
The guidance [4] further states that patients whose treatment with vedolizumab is not recommended, but was 
started within the NHS before this guidance was published, should be able to continue treatment until they and 
their NHS clinician consider it appropriate to stop 
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5.1. Consideration of Clinical and Cost-Effectiveness Issues 
This section discusses the key issues considered by the Appraisal Committee. The full list can be found in the 
$SSUDLVDO&RPPLWWHH¶Vfinal appraisal document (FAD) [4]. 
 
5.1.1. Generalisability of the GEMINI trials [12, 13] to the likely use and population to receive 
vedolizumab in clinical practice in England 
The Committee [4] considered the generalisability of the populations enrolled in the GEMINI II [12] and III 
[13] to the populations that would be eligible to receive vedolizumab in clinical practice in England. The 
Committee heard from clinical experts that only a few number of patients seen in clinical practice have a CDAI 
above 450 and therefore considered the spectrum of disease activity of patients included in the trial broadly 
comparable to that seen in clinical practice. The Committee also discussed the induction regimens used in the 
GEMINI trials [12, 13] and heard from the clinical experts that induction response would usually be assessed 
later than observed in the trials. The Committee considered that the two populations (anti-TNF-Į naïve and 
failure) needed to be evaluated separately and that assessing response at week 6, as in the GEMINI trials would 
not detect all patients whose disease respond to therapy. 
 
5.1.2. Clinical effectiveness of vedolizumab 
The Committee [4] discussed the efficacy estimates for vedolizumab from the GEMINI II trial [12] at the 
induction phase compared with placebo and noted that vedolizumab was more effective at week 6 in inducing 
clinical remission in the ITT mixed population, patients who had not had an anti-TNF-Į, and patients in whom 
an anti-TNF-ĮKDGIDLOHG The Committee considered the efficacy estimates for vedolizumab from the GEMINI 
III trial [13] at the induction phase compared with placebo and noted that whilst vedolizumab did not meet the 
primary outcome for inducing a better clinical remission compared with placebo at week 6 in patients in whom 
anti-TNF-Į KDG IDLOHG a statistically significant benefit was observed in week 10. The Committee then 
discussed the efficacy estimates for vedolizumab at the maintenance phase compared with placebo and noted 
that only GEMINI II provided 52 weeks evidence for this outcome. The Committee noted that vedolizumab 
showed higher remission rates than placebo in the mixed ITT population, patients who had never had anti-TNF-
Į, and patients in whom anti-TNF-ĮKDVIDLOHG7KHCommittee also heard from the clinical experts that even a 
small absolute treatment effect would be perceived as beneficial given the absence of alternative treatment 
options. After consideration of the clinical evidence, the Committee concluded that vedolizumab improved 
clinical remission at the induction phase and that vedolizumab was more effective compared with place in 
maintaining response up to 52 weeks in patients who had never had anti-TNF-ĮDQGpatients in whom anti-TNF-
ĮKDVIDLOHG  
The Committee [4] also considered the results from the NMA to estimate the relative effectiveness of 
vedolizumab compared with adalimumab and infliximab but concluded that results from the NMA were too 
uncertain in light of the ERG¶V comments and testimony from the clinical experts.  
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Finally, the Committee considered the evidence presented on the impact of vedolizumab on health-related 
quality of life and identified discrepancies on the reporting of the EQ-5D. These discrepancies could not be 
explained by the company and therefore the Committee was not able to conclude whether vedolizumab would 
have an effect on the EQ-5D value but noted that results using other assessment tools suggested that 
vedolizumab could improve quality of life.  
 
5.1.3. Uncertainties around the model structure and plausibility of assumptions and inputs used in the 
economic model 
The Committee [4] considered the model structure used by the company and concluded that it was uncertain 
whether the model was structurally sound in light of the number of concerns expressed by the ERG, but that, 
overall, it was acceptable to inform its decision-making. The Committee then went on to discuss the dosing 
assumptions and assessment of response used in the economic model and considered that the dosing 
assumptions used in the revised economic model was appropriate. 
The Committee discussed the discontinuation rule assumed by the company whereby biologic treatments would 
be stopped after a maximum of one year. The Committee heard from the clinical experts that patients at high 
risk of relapse or surgery are likely to remain on treatment after one year but that they would try to stop 
treatment if it was not needed. The Committee considered that the assumption made by the company was not 
unreasonable, but that in clinical practice, patients could be treated for longer. 
The Committee [4] considered whether the time horizon used in the original model (10 years) was appropriate 
and concluded that, whilst there was uncertainty in the long-term extrapolation given the short amount of data 
available, the use of a lifetime horizon in the revised economic model was more appropriate. 
The Committee considered the modelling of long-term AEs and noted that AEs associated with the long-term 
use of corticosteroids such as diabetes and osteoporosis were not included and were likely to improve the cost-
effectiveness for vedolizumab compared with conventional non-biological treatments. 
Finally, the Committee considered the modelling of surgery, health state costs, mortality rate and was generally 
satisfied with the assumptions used in the revised economic model but highlighted that there was some 
uncertainties. 
 
6. Conclusion 
Vedolizumab appears to be more effective in both the induction and maintenance phase compared with placebo 
in patients with moderate-to-severe active CURKQ¶V disease who have had an inadequate response to, loss of 
response to, or intolerance to conventional therapy or anti-TNF-Į. The effectiveness of vedolizumab compared 
with adalimumab and infliximab is unknown and uncertain in the absence of head-to-head randomised 
controlled trial and differences between studies included the network meta-analysis. The ERG identified a 
number of limitations which were believed to limit the robustness of the results presented by the company. 
These limitations could not be addressed by the ERG without major restructuring of the economic model. 
Therefore, the ERG concluded thDWUHVXOWVIURPWKHFRPSDQ\¶VPRGHOQHHGHGWREHLQWHUSUHWHGZLWKFDXWLRQDQG
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that it was unclear whether the ICERs would increase or decrease following amendment of the identified 
structural issues. Nevertheless, the Committee considered that, on balance, after taking into account the 
uncertainty in the modelling of the long-term treatment effect of vedolizumab and structural assumptions, the 
absence of modelling of long-term AEs associated with corticosteroids and the high unmet need in patients in 
whom anti-TNF-ĮKDVIDLOHGYHGROL]XPDEFRXOGEHFRQVLGHUHGFRVW-effective and recommended vedolizumab in 
this population, providing the company provides vedolizumab with the discount agreed in the patient access 
scheme [4]. The Committee [4] also considered the high unmet need of a subgroup of patients who cannot take 
anti-TNF-Į DQG LQ ZKRP YHGROL]XPDE would provide the only medical alternative to conventional non-
biological therapy and concluded that vedolizumab could be prescribed for this population providing the 
company provides vedolizumab with the discount agreed in the patient access scheme. The Committee [4] did 
not recommend the use of vedolizumab in patients who had never had anti-TNF-Į and were able to receive 
them. 
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